-
1 month ago | 
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
Bringing this interview with Andrew Kuykendall, MD, clinical researcher at Moffitt Cancer Center, to a close, he addresses safety concerns that have been linked to the injectable hepcidin mimetic rusfertide (Takeda) and its overall impact on patient quality of life. Rusfertide is under investigation for treatment of polycythemia vera, a myeloproliferative neoplasm, in the ongoing phase 3 VERIFY trial (NCT05210790), on which Kuykendall is an investigator.
-
1 month ago | 
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
With an expected completion date sometime in June, the phase 3 VERIFY trial (NCT05210790) will soon conclude its investigation of rusfertide (Takeda) as add-on therapy to a patient’s current course of treatment for their polycythemia vera. The investigative agent has already received breakthrough therapy, orphan drug, and fast track designations from the FDA.
-
2 months ago | 
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
The investigational rusfertide (Takeda), is currently being evaluated in the phase 3 VERIFY trial (NCT05210790) as an injectable therapeutic to treat polycythemia vera (PV) through achieving and sustaining hematocrit control. This agent has already breakthrough therapy, orphan drug, and fast track designations from the FDA.
-
2 months ago | 
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
In early March, The American Journal of Managed Care® spoke with Andrew Kuykendall, MD, a clinical researcher at Moffitt Cancer Center who focuses on myeloproliferative neoplasms (MPNs), myelodysplastic syndrome/MPN overlap syndromes, and systemic mastocytosis.
-
Mar 5, 2025 | 
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. Several medications are approved to treat this condition—among them ruxolitinib (Jakafi; Incyte), in December 2014,1 and ropeginterferon alfa-2b-njft (Besremi; PharmaEssentia), in November 20212—and others remain in clinical development.
-
Feb 28, 2025 | 
onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani
OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss key accomplishments in the myeloproliferative neoplasm (MPN) space, highlighting pivotal developments that have shaped clinical practice, and share their excitement for 2025, including areas primed for significant progress and goals for the coming year. Video content above is prompted by the following:What accomplishments in the MPN space are you most proud of? Which developments stand out as pivotal in shaping clinical practice?
-
Feb 28, 2025 | 
onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani
OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss noteworthy updates in myelofibrosis (MF) from ASH 2024, share their views on the future of MF treatment, offer clinical pearls for community oncologists, and highlight emerging pathways and targets they are excited about for MF management. Video content above is prompted by the following:Dr Kuykendall to faculty: What outstanding updates in MF from ASH 2024 are noteworthy?
-
Feb 28, 2025 | 
onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani
OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss studies aimed at combating dose-dependent anemia as a consequence of Janus kinase inhibitors (JAKi) treatment and share their thoughts on potential strategies to address this challenge. Video content above is prompted by the following:Dr Kuykendall to faculty: Dose-dependent anemia can be a consequence of treatment with JAKi. What are your thoughts on studies aimed at combating this challenge?
-
Feb 21, 2025 | 
onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani
Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and PracticePanelists discuss the types of questions that real-world (RW) data can answer in comparison to with clinical trial data, and how it they can complement clinical findings in treatment decision-making.
-
Feb 21, 2025 | 
onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani
Panelists discuss data from the FREEDOM2 trial and its sub-analysis on low platelet count with fedratinib (FEDR), as well as the pooled analysis of the COMFORT-I/-II trials on ruxolitinib (RUX) for myelofibrosis.
